Originally published Thursday, March 13, 2008 at 12:00 AM
FDA accelerates timetable in Dendreon's drug study
Federal regulators agreed to new rules for a key clinical study on Dendreon's experimental prostate-cancer drug Provenge, fast-forwarding...
Seattle Times business reporter
Federal regulators agreed to new rules for a key clinical study on Dendreon's experimental prostate-cancer drug Provenge, fast-forwarding the study's final results by one year.
The move does not change the Seattle company's most optimistic target date for approval of its product, which would be based on interim data.
The U.S. Food and Drug Administration said previously it could give its blessing if an early review of the results shows the drug's effectiveness at improving the survival rate of prostate-cancer patients.
A Dendreon executive said Wednesday the company still expects to present interim data in the second half of this year.
Nevertheless, if the interim data fail to pass muster with the regulators, Provenge will have another chance when the final results are in next year, rather than in 2010.
"We have two very real shots on goal," said Chief Financial Officer Greg Schiffman. The trial's redesign "really accelerates the second one without hurting the first one."
The news seemed to reassure investors: Dendreon stock surged 7.3 percent to $5.29 a share.
It was also a glimmer of hope for many prostate-cancer patients vexed by the FDA's decision last May not to approve the drug for lack of sufficient proof of efficacy.
"It's good news: sooner is better than later," said McAdams Wright Ragen analyst Paul Latta.
The redesign of the closely followed clinical trial is the latest episode in the Provenge saga, which has been at the epicenter of an intense debate over whether the FDA's approval of potentially lifesaving drugs should be sped up or made stricter after recent safety scandals.
Hopes for Provenge rode high last March, after an expert panel recommended the drug.
But in May the FDA said more information was needed, making Dendreon shares plummet.
![]()
Patient advocates and angry investors accused some panel members of lobbying against Provenge due to conflicts of interest.
The advocates — through organizations like CareToLive and A Right To Live — have waged a vigorous campaign against the FDA that included demonstrations, lawsuits, and Freedom of Information Act requests for internal agency documents.
Three members of Congress requested hearings, but in February a congressional committee declined to look into the matter so as not to interfere with the agency's regulatory process.
The move to speed up the clinical trial was initiated by Dendreon as part of its business strategy, and is unrelated to the political controversies surrounding Provenge, Schiffman said.
Ángel González: 206-515-5644 or agonzalez@seattletimes.com
Copyright © 2008 The Seattle Times Company
Nintendo re-enlists Mario, savior of video-game industry
Verizon-Frontier deal stirs concern among consumers
Brier Dudley: 'Guitar Hero' founder excited about future
Gaps for consumers in Democrat health care bills
Hutch gets $10M from Bezos family for immunotherapy research

Real Salt Lake wins MLS Cup
Real Salt Lake defeated the Los Angeles Galaxy with penalty kicks after 120 minutes of play at Qwest Field in Seattle.
general classifieds
Garage & estate salesFurniture & home furnishings
Sporting goods
just listed
42" Hitachi Plasma 1080i - $500
8 Drawer Dresser with Attached Mirror - $200
8 seat pecon formal dining table and china hutch - $1500
More listings
POST A FREE LISTING
shopping
Give yourself a treat and visit Watson Kennedy's Holiday Open Houses
More minding the store
events for Monday, Nov. 23
- Castle Discount with Military ID
- CraftsGiving
- Alhambra 20 Percent Off Jewelry Sale
- Dish It Up! Totally Truffles
editors' picks
- Phinney Ridge & Greenwood shopping
- Independent video stores
- Pioneer Square shopping
- Garden furnishings
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Tugboat sinks at Seattle waterfront pier
- Illegal workers quietly let go
- Child-support error costs nearly $21,000
- Vikings easily beat the Seahawks
- Craigslist adoption ad: A plea by young mother-to-be? A scam?
- Chase shrugs off loss of CD investors
- Woman stabbed by stranger in North Seattle
- Snow piles up on Cascade slopes
- Denny Triangle gains skyline, but tenants slow to come
- Illegal workers quietly let go
373 - Climate change speeds up since 1997 Kyoto accord
210 - Metro won't cut bus service after all
151 - New Husky recruit: Enes Kanter
97 - Historic health care bill clears Senate hurdle
95 - Tattoos at Mill Creek Church pierce skin, soul
83 - Middleton says Huskies "plan on scoring at least 50 points'' Saturday
82 - Jerry Brewer: Seahawks can't lean on the Hutch Crutch now
74 - UW, WSU once again meet to see who's worse
68 - Seattle woman charged with knife attack on boyfriend's ex
65
- Sprouts, raw fish on attorney's 'do not eat' list
- Tattoos at Mill Creek church pierce skin, soul
- Food-safety lawyer's wish: Put me out of business
- Illegal workers quietly let go
- Architects, chefs find 'kid' within to build Gingerbread Village
- Rediscovering Moab, 'the most beautiful place on Earth'
- It's possible to recover a life lost to hoarding
- Child-support error costs nearly $21,000
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Taste | The Great Pie Bake-off pits friends and fruit

